Tempest Therapeutics
TPST
63 hedge funds and large institutions have $41.9M invested in Tempest Therapeutics in 2017 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 17 reducing their positions, and 24 closing their positions.
2,000% more call options, than puts
Call options by funds: $21K | Put options by funds: $1K
32% more capital invested
Capital invested by funds: $31.7M → $41.9M (+$10.2M)
24% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 17
25% less funds holding
Funds holding: 84 → 63 (-21)
63% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$5.59M |
| 2 |
BlackRock
New York
|
+$2.98M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$596K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$545K |
| 5 |
GC
GMT Capital
Atlanta,
Georgia
|
+$368K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
CQS Cayman
Camana Bay, Grand Cayman,
Cayman Islands
|
-$1.05M |
| 2 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$1.02M |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$637K |
| 4 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$331K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$289K |
TPST Hedge Fund Activity: Q1 2017 in Review
63 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q1 2017, worth a combined $41.9M — up 32% from $31.7M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of TPST and 9 opened new positions — a net loss of 15 holders — while 17 trimmed existing stakes and 13 added.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $5.59M. The largest seller was CQS Cayman, exiting entirely with an estimated $1.05M sold.
- 63 institutional investors held Tempest Therapeutics (TPST) as of Q1 2017, down from 84 in Q4 2016.
- Funds reported $41.9M of Tempest Therapeutics stock for Q1 2017, up 32% quarter-over-quarter.
- 9 funds opened new Tempest Therapeutics positions in Q1 2017 and 24 closed out, a net change of -15 holders.
- The largest Tempest Therapeutics buyer in Q1 2017 was EcoR1 Capital, an estimated $5.59M added.
- The largest Tempest Therapeutics seller in Q1 2017 was CQS Cayman, an estimated $1.05M sold.
Based on aggregated 13F filings for Q1 2017.